Theravance Biopharma
CompanyUnited StatesFounded 2013
Theravance Biopharma develops one asset, approved (Revefenacin). Mostly small molecule acting on CHRM3; based in the United States, founded in 2013.
- 1
- Asset
- Furthest stage
- Approved
- 2
- Trials
- 0
- Signals
Pipeline
1Long-acting muscarinic antagonist that induces bronchodilation by inhibiting acetylcholine in airway smooth muscle.
Approved, Small molecule, CHRM3, chronic obstructive pulmonary disease (Phase 3), unspecified health condition 1: J449- chronic obstructive pulmonary disease (Phase 3)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials4
- Signals1
- Similar companies6